Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Table: Safety of drugs for IBS in pregnancy and lactation (online only).

The Medical letter on drugs and therapeutics

[No authors listed]
PMID: 32324174
Med Lett Drugs Ther. 2020 Mar 23;62(1594):e48-e49.

No abstract available.

Cite
Table: Safety of drugs for IBS in pregnancy and lactation (online only). Med Lett Drugs Ther. 2020;62(1594):e48-e49
(2020). Table: Safety of drugs for IBS in pregnancy and lactation (online only). The Medical letter on drugs and therapeutics, 62(1594), e48-e49.
"Table: Safety of drugs for IBS in pregnancy and lactation (online only)." The Medical letter on drugs and therapeutics vol. 62,1594 (2020): e48-e49.
Table: Safety of drugs for IBS in pregnancy and lactation (online only). Med Lett Drugs Ther. 2020 Mar 23;62(1594):e48-e49. PMID: 32324174.
Copy Download .nbib Format: NLM
Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?.

Maedica

Onut R, Balanescu AP, Constantinescu D, Calmac L, Marinescu M, Dorobantu PM.
PMID: 23399970
Maedica (Bucur). 2012 Jun;7(2):153-62.

Carotid intima-media thickness (CIMT) can be reliably determined in vivo by carotidian ultrasound and is an accessible and reliable method to assess subclinical atherosclerosis. Available epidemiological data showed that CIMT is significantly correlated with future cardiovascular events. However it...

Cite
Onut R, Balanescu AP, Constantinescu D, et al. Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?. Maedica (Bucur). 2012;7(2):153-62
Onut, R., Balanescu, A. P., Constantinescu, D., Calmac, L., Marinescu, M., & Dorobantu, P. M. (2012). Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?. Maedica, 7(2), 153-62.
Onut, Roxana, et al. "Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?." Maedica vol. 7,2 (2012): 153-62.
Onut R, Balanescu AP, Constantinescu D, Calmac L, Marinescu M, Dorobantu PM. Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?. Maedica (Bucur). 2012 Jun;7(2):153-62. PMID: 23399970; PMCID: PMC3557424.
Copy Download .nbib Format: NLM
Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature.

Oncology and therapy

Kruse ML, Kang IM, Bagegni NA, Howell WT, Moore HCF, Bedell CH, Stokoe CT.
PMID: 34800263
Oncol Ther. 2021 Nov 20; doi: 10.1007/s40487-021-00178-w. Epub 2021 Nov 20.

INTRODUCTION: Neratinib and neratinib-based combinations have demonstrated efficacy for treatment of human epidermal growth factor receptor 2-positive (HER2+) early-stage and metastatic breast cancers. However, diarrhea has been reported as a common adverse event leading to neratinib discontinuation. Results from...

Cite
Kruse ML, Kang IM, Bagegni NA, et al. Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncol Ther. 2021;doi: 10.1007/s40487-021-00178-w.
Kruse, M. L., Kang, I. M., Bagegni, N. A., Howell, W. T., Moore, H. C. F., Bedell, C. H., & Stokoe, C. T. (2021). Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncology and therapy, . https://doi.org/10.1007/s40487-021-00178-w
Kruse, Megan L, et al. "Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature." Oncology and therapy vol. (2021). doi: https://doi.org/10.1007/s40487-021-00178-w
Kruse ML, Kang IM, Bagegni NA, Howell WT, Moore HCF, Bedell CH, Stokoe CT. Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncol Ther. 2021 Nov 20; doi: 10.1007/s40487-021-00178-w. Epub 2021 Nov 20. PMID: 34800263; PMCID: PMC8605449.
Copy Download .nbib Format: NLM
Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol.

Journal of cardiovascular pharmacology and therapeutics

Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM.
PMID: 10684408
J Cardiovasc Pharmacol Ther. 1996 Apr;1(2):117-122. doi: 10.1177/107424849600100205.

BACKGROUND: Atorvastatin, a new HMG-CoA reductase inhibitor in clinical development has demonstrated an acceptable safety profile and marked cholesterol and triglyceride reduction at doses ranging from 10-80 mg/day. Since bile acid sequestering resins are often used in combination with...

Cite
Heinonen TM, Schrott H, McKenney JM, et al. Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. J Cardiovasc Pharmacol Ther. 1996;1(2):117-122doi: 10.1177/107424849600100205.
Heinonen, T. M., Schrott, H., McKenney, J. M., Sniderman, A. D., Broyles, F. E., Zavoral, J. H., Kivel, F., & Black, D. M. (1996). Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. Journal of cardiovascular pharmacology and therapeutics, 1(2), 117-122. https://doi.org/10.1177/107424849600100205
Heinonen, et al. "Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol." Journal of cardiovascular pharmacology and therapeutics vol. 1,2 (1996): 117-122. doi: https://doi.org/10.1177/107424849600100205
Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. J Cardiovasc Pharmacol Ther. 1996 Apr;1(2):117-122. doi: 10.1177/107424849600100205. PMID: 10684408.
Copy Download .nbib Format: NLM
Chronic Diarrhea.

Current treatment options in gastroenterology

Schiller LR.
PMID: 15913515
Curr Treat Options Gastroenterol. 2005 Jun;8(3):259-266. doi: 10.1007/s11938-005-0018-8.

Chronic diarrhea can be due to any of several hundred conditions. When investigation fails to uncover a specific cause that can be treated successfully, nonspecific therapy is implemented. This includes dietary alterations if specific aggravating foods can be identified,...

Cite
Schiller LR. Chronic Diarrhea. Curr Treat Options Gastroenterol. 2005;8(3):259-266doi: 10.1007/s11938-005-0018-8.
Schiller, L. R. (2005). Chronic Diarrhea. Current treatment options in gastroenterology, 8(3), 259-266. https://doi.org/10.1007/s11938-005-0018-8
Schiller, Lawrence R. "Chronic Diarrhea." Current treatment options in gastroenterology vol. 8,3 (2005): 259-266. doi: https://doi.org/10.1007/s11938-005-0018-8
Schiller LR. Chronic Diarrhea. Curr Treat Options Gastroenterol. 2005 Jun;8(3):259-266. doi: 10.1007/s11938-005-0018-8. PMID: 15913515.
Copy Download .nbib Format: NLM
Managing bile acid diarrhoea.

Therapeutic advances in gastroenterology

Walters JR, Pattni SS.
PMID: 21180614
Therap Adv Gastroenterol. 2010 Nov;3(6):349-57. doi: 10.1177/1756283X10377126.

Bowel symptoms including diarrhoea can be produced when excess bile acids (BA) are present in the colon. This condition, known as bile acid or bile salt malabsorption, has been under recognized, as the best diagnostic method, the (75)Se-homocholic acid...

Cite
Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010;3(6):349-57doi: 10.1177/1756283X10377126.
Walters, J. R., & Pattni, S. S. (2010). Managing bile acid diarrhoea. Therapeutic advances in gastroenterology, 3(6), 349-57. https://doi.org/10.1177/1756283X10377126
Walters, Julian R F, and Pattni, Sanjeev S. "Managing bile acid diarrhoea." Therapeutic advances in gastroenterology vol. 3,6 (2010): 349-57. doi: https://doi.org/10.1177/1756283X10377126
Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010 Nov;3(6):349-57. doi: 10.1177/1756283X10377126. PMID: 21180614; PMCID: PMC3002596.
Copy Download .nbib Format: NLM
Dose--Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia.

American journal of therapeutics

Hunninghake DB, Stein EA, Bremner WF, Greenland P, Demke DM, Oliphant TH.
PMID: 11847550
Am J Ther. 1995 Mar;2(3):180-189. doi: 10.1097/00045391-199503000-00006.

The purpose of the study was to evaluate the efficacy and safety of a new formulation of colestipol provided in table form. This was a randomized, double-blind, placebo-controlled, multicenter, dose-ranging study. A total of 196 patients with primary hypercholesterolemia...

Cite
Hunninghake DB, Stein EA, Bremner WF, et al. Dose--Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia. Am J Ther. 1995;2(3):180-189doi: 10.1097/00045391-199503000-00006.
Hunninghake, D. B., Stein, E. A., Bremner, W. F., Greenland, P., Demke, D. M., & Oliphant, T. H. (1995). Dose--Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia. American journal of therapeutics, 2(3), 180-189. https://doi.org/10.1097/00045391-199503000-00006
Hunninghake, Donald B., et al. "Dose--Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia." American journal of therapeutics vol. 2,3 (1995): 180-189. doi: https://doi.org/10.1097/00045391-199503000-00006
Hunninghake DB, Stein EA, Bremner WF, Greenland P, Demke DM, Oliphant TH. Dose--Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia. Am J Ther. 1995 Mar;2(3):180-189. doi: 10.1097/00045391-199503000-00006. PMID: 11847550.
Copy Download .nbib Format: NLM
Treatment of Biliary Problems in Inflammatory Bowel Disease.

Current treatment options in gastroenterology

Huang CS, Lichtenstein DR.
PMID: 15769433
Curr Treat Options Gastroenterol. 2005 Apr;8(2):117-126. doi: 10.1007/s11938-005-0004-1.

The most common biliary problem in patients with inflammatory bowel disease is primary sclerosing cholangitis (PSC). The treatment of this disease is multifaceted and frequently requires a multidisciplinary approach involving internists, nutritionists, gastroenterologists, and surgeons. Unfortunately, other than liver...

Cite
Huang CS, Lichtenstein DR. Treatment of Biliary Problems in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8(2):117-126doi: 10.1007/s11938-005-0004-1.
Huang, C. S., & Lichtenstein, D. R. (2005). Treatment of Biliary Problems in Inflammatory Bowel Disease. Current treatment options in gastroenterology, 8(2), 117-126. https://doi.org/10.1007/s11938-005-0004-1
Huang, Christopher S, and Lichtenstein, David R. "Treatment of Biliary Problems in Inflammatory Bowel Disease." Current treatment options in gastroenterology vol. 8,2 (2005): 117-126. doi: https://doi.org/10.1007/s11938-005-0004-1
Huang CS, Lichtenstein DR. Treatment of Biliary Problems in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005 Apr;8(2):117-126. doi: 10.1007/s11938-005-0004-1. PMID: 15769433.
Copy Download .nbib Format: NLM
A US military perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Remund DD, Sutton EL.
PMID: 16674545
Value Health. 1998 Nov;1(4):228-30. doi: 10.1046/j.1524-4733.1998.140228.x.

This paper discusses lipid therapy decision-making at the population level within the United States (US) Military Health Services System. The US Military Health Services System serves approximately 8.2 million beneficiaries fairly representative of the general population. Of its $680...

Cite
Remund DD, Sutton EL. A US military perspective. Value Health. 1998;1(4):228-30doi: 10.1046/j.1524-4733.1998.140228.x.
Remund, D. D., & Sutton, E. L. (1998). A US military perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 1(4), 228-30. https://doi.org/10.1046/j.1524-4733.1998.140228.x
Remund, D D, and Sutton, E L. "A US military perspective." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 1,4 (1998): 228-30. doi: https://doi.org/10.1046/j.1524-4733.1998.140228.x
Remund DD, Sutton EL. A US military perspective. Value Health. 1998 Nov;1(4):228-30. doi: 10.1046/j.1524-4733.1998.140228.x. PMID: 16674545.
Copy Download .nbib Format: NLM
Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials.

BMJ open

Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T, Knop FK.
PMID: 23148345
BMJ Open. 2012 Nov 12;2(6). doi: 10.1136/bmjopen-2012-001803. Print 2012.

INTRODUCTION: In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by...

Cite
Hansen M, Sonne DP, Mikkelsen KH, et al. Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open. 2012;2(6)doi: 10.1136/bmjopen-2012-001803.
Hansen, M., Sonne, D. P., Mikkelsen, K. H., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2012). Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ open, 2(6), . https://doi.org/10.1136/bmjopen-2012-001803
Hansen, Morten, et al. "Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials." BMJ open vol. 2,6 (2012). doi: https://doi.org/10.1136/bmjopen-2012-001803
Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T, Knop FK. Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open. 2012 Nov 12;2(6). doi: 10.1136/bmjopen-2012-001803. Print 2012. PMID: 23148345; PMCID: PMC3533035.
Copy Download .nbib Format: NLM
Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia.

Journal of cardiovascular pharmacology and therapeutics

Isaacsohn JL, Bakker-Arkema RG, Fayyad R, Whitcomb R, Black DM.
PMID: 10684465
J Cardiovasc Pharmacol Ther. 1997 Oct;2(4):243-249. doi: 10.1177/107424849700200402.

BACKGROUND: Atorvastatin calcium (Lipitor) is a new 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. The present study was conducted to examine the effect of pronounced cholesterol lowering on adrenal function in patients with severe hypercholesterolemia. METHODS AND RESULTS: Adrenal function was...

Cite
Isaacsohn JL, Bakker-Arkema RG, Fayyad R, et al. Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997;2(4):243-249doi: 10.1177/107424849700200402.
Isaacsohn, J. L., Bakker-Arkema, R. G., Fayyad, R., Whitcomb, R., & Black, D. M. (1997). Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia. Journal of cardiovascular pharmacology and therapeutics, 2(4), 243-249. https://doi.org/10.1177/107424849700200402
Isaacsohn, et al. "Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia." Journal of cardiovascular pharmacology and therapeutics vol. 2,4 (1997): 243-249. doi: https://doi.org/10.1177/107424849700200402
Isaacsohn JL, Bakker-Arkema RG, Fayyad R, Whitcomb R, Black DM. Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997 Oct;2(4):243-249. doi: 10.1177/107424849700200402. PMID: 10684465.
Copy Download .nbib Format: NLM
Lymphocytic and Collagenous Colitis: Medical Management.

Current treatment options in gastroenterology

Marshall JK, Irvine EJ.
PMID: 11096583
Curr Treat Options Gastroenterol. 1999 Apr;2(2):127-133. doi: 10.1007/s11938-999-0040-3.

When possible, patients taking nonsteroidal anti-inflammatory medications should discontinue them when the diagnosis of microscopic colitis is made. Although there is no direct evidence of its efficacy, a trial of elimination of caffeine or lactose or both should be...

Cite
Marshall JK, Irvine EJ. Lymphocytic and Collagenous Colitis: Medical Management. Curr Treat Options Gastroenterol. 1999;2(2):127-133doi: 10.1007/s11938-999-0040-3.
Marshall, J. K., & Irvine, E. J. (1999). Lymphocytic and Collagenous Colitis: Medical Management. Current treatment options in gastroenterology, 2(2), 127-133. https://doi.org/10.1007/s11938-999-0040-3
Marshall, and Irvine. "Lymphocytic and Collagenous Colitis: Medical Management." Current treatment options in gastroenterology vol. 2,2 (1999): 127-133. doi: https://doi.org/10.1007/s11938-999-0040-3
Marshall JK, Irvine EJ. Lymphocytic and Collagenous Colitis: Medical Management. Curr Treat Options Gastroenterol. 1999 Apr;2(2):127-133. doi: 10.1007/s11938-999-0040-3. PMID: 11096583.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries